Elsevier, Metabolic Steatotic Liver Disease: Current Knowledge, Therapeutic Treatments, and Future Directions, 2024, Pages 261-275
This content aligns with Goal 3: Good Health as this chapter will review the aspects of combined viral hepatitis and FLD, including prevalence, risk factors, natural history, pathogenesis, and management to help inform the reader of the complexity of these liver diseases.
Elsevier, Viral, Parasitic, Bacterial, and Fungal Infections: Antimicrobial, Host Defense, and Therapeutic Strategies, 2023, Pages 87-99
This content aligns with Goal 3: Good Health. Provides a firm understanding of the undulating interplay between liver graft function and a patient’s risk for infection.
Elsevier, Viral, Parasitic, Bacterial, and Fungal Infections: Antimicrobial, Host Defense, and Therapeutic Strategies, 2023, Pages 757-770
This content aligns with Goal 3: Good Health. As per World Health Organization (WHO) recommendations, it is required to implement the evaluation studies of ethnomedicines for HIV/AIDS, malaria, tuberculosis, and other infectious treatments, to find effective and economical therapeutic agents.
Elsevier, Advanced Vaccination Technologies for Infectious and Chronic Diseases: A Guide to Vaccinology, Developments in Immunology, 2024, Pages 51-62
This content aligns with Goal 3: Good Health. Presents the successful influenza vaccines (using hemagglutinin and neuraminidase proteins), hepatitis B surface antigen vaccine, and the human papillomavirus vaccines targeting viral capsid proteins.
This content aligns with Goal 3: Good Health, this chapter aims at elucidating the main characteristics of AIH, PBC, and PSC, with particular interest for the clinical manifestations, pathogenesis, autoantibodies, and therapeutic options.
Elsevier, Oncogenic Viruses, Volume 2: Medical Applications of Viral Oncology Research, 2023, Pages 173-189
This content aligns with Goal 3: Good Health. Hepatitis B remains a worrying health problem for several countries. Although vaccination has clearly been shown to be very effective in the prevention and control of the disease globally, the emergence of mutant resistant liver infections is of concern. Thus the development of new common vaccines for the prevention of all types of hepatitis is warranted.
Elsevier, Infection and Autoimmunity (Third Edition), 2024, Pages 317-335
This content aligns with Goal 3: Good Health by describing cronic infection due to hepatitis C virus (HCV) that is among the most common etiologic factors of vasculitis in humans.